Argent BiopharmaRGTLF Market Cap is $2.84 Mil as of Jun. 25, 2026. The stock has 8 warning signs investors should review. Among 1,023 Drug Manufacturers companies, Argent Biopharma ranks worse than 93.35% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Argent Biopharma's share price for the quarter that ended in Dec. 2025 was $0.055. Argent Biopharma's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 83.39 Mil. Therefore, Argent Biopharma's market cap for the quarter that ended in Dec. 2025 was $4.59 Mil.
Argent Biopharma's quarterly market cap
declined
from Dec. 2024 ($6.33 Mil) to Jun. 2025 ($3.69 Mil) but then
increased
from Jun. 2025 ($3.69 Mil) to Dec. 2025 ($4.59 Mil).
Argent Biopharma's annual market cap
declined
from Jun. 2023 ($13.40 Mil) to Jun. 2024 ($9.62 Mil) and
declined
from Jun. 2024 ($9.62 Mil) to Jun. 2025 ($3.69 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Argent Biopharma's Enterprise Value for Today is $8.04 Mil.
Argent Biopharma (OTCPK:RGTLF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Argent Biopharma Market Cap Related Terms
Argent Biopharma Market Cap Historical Data
* Premium members only.
The historical data trend for Argent Biopharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Argent Biopharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Argent Biopharma Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Argent Biopharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Argent Biopharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Argent Biopharma's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Argent Biopharma (RGTLF) has a Market Cap of $2.84 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Argent Biopharma and its competitors. According to the industry distribution chart, Argent Biopharma ranks #955 out of 1023 companies in the Drug Manufacturers industry, placing it in the top 93.4%.
Is Argent Biopharma's Market Cap too high?
Argent Biopharma's current Market Cap is $2.84 Mil. The Drug Manufacturers industry median Market Cap is 207.38. Argent Biopharma's value of $2.84 Mil is 98.6% below this industry median. Based on the distribution chart, Argent Biopharma ranks #955 out of 1023 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Argent Biopharma's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Argent Biopharma ranks #955 out of 1023 companies for Market Cap. This places Argent Biopharma in the lower half of its industry. The industry median Market Cap is 207.38. Argent Biopharma's value of $2.84 Mil is 98.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 207.38, based on 1,023 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Argent Biopharma's current Market Cap of $2.84 Mil is 98.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Argent Biopharma and its competitors. For the Drug Manufacturers industry, the median Market Cap is 207.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Argent Biopharma's current Market Cap is $2.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argent Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Argent Biopharma (RGTLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 25% above its estimated fair value. The current Market Cap is $2.84 Mil and 98.6% below the Drug Manufacturers industry median of 207.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Argent Biopharma (RGTLF), the current Market Cap is $2.84 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Argent Biopharma Ltd is a clinical-stage biopharmaceutical company pioneering nano-engineered therapeutics that reset the balance between the nervous and immune systems. Its assets, CannEpil and CimetrA, target immune dysregulation in drug-resistant epilepsy and cytokine-driven inflammatory disorders, respectively. The products of the company include CannEpil for refractory epilepsy and cerebral palsy, CimetrA for acute lung injury and ARDS, and CogniCann for enhancing the quality of life in dementia and Alzheimer's patients, with additional treatments in development, and others. Its geographic areas are Malta, Slovenia and others, and Australia. The group generates the majority of its revenue from Slovenia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RGTLF has been successfully added to your 